However, tumor weights from mice receiving the 30% CR + IGF-1 regimen were not statistically different from either CR or control mice, suggesting the IGF-1 infusion partially rescued the reduced mammary tumor growth observed in CR mice. The gene discussed is IGF1; the disease is neoplasm.